National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings, 2168-2169 [2022-00527]
Download as PDF
<![CDATA[
jspears on DSK121TN23PROD with NOTICES1
2168
Federal Register / Vol. 87, No. 9 / Thursday, January 13, 2022 / Notices
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Eleni Apostolos Liapi, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20817, (301) 867–5309, eleni.liapi@nih.gov.
Name of Committee: Digestive, Kidney and
Urological Systems Integrated Review Group;
Kidney and Urological Systems Function and
Dysfunction Study Section.
Date: February 17–18, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ganesan Ramesh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892, (301) 827–
5467, ganesan.ramesh@nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Clinical Integrative Cardiovascular
and Hematological Sciences Study Section.
Date: February 17–18, 2022.
Time: 9:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Margaret Chandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4126,
MSC 7814, Bethesda, MD 20892, (301) 435–
1743, margaret.chandler@nih.gov.
Name of Committee: Biology of
Development and Aging Integrated Review
Group; Mechanisms of Cancer
Therapeutics—1 Study Section.
Date: February 17–18, 2022.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maria Dolores Arjona
Mayor, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institute of Health, 6701 Rockledge Drive,
Room 806D, Bethesda, MD 20892, (301) 827–
8578, dolores.arjonamayor@nih.gov.
Name of Committee: Molecular, Cellular
and Developmental Neuroscience Integrated
Review Group; Molecular and Cellular
Neuropharmacology Study Section.
Date: February 17–18, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Vanessa S. Boyce, Ph.D.,
Scientific Review Officer, Center for
VerDate Sep<11>2014
18:18 Jan 12, 2022
Jkt 256001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Rm. 4185,
MSC 7850, Bethesda, MD 20892, (301) 402–
3726, boycevs@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group; Learning, Memory
and Decision Neuroscience Study Section.
Date: February 17–18, 2022.
Time: 9:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Roger Janz, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 402–8515, janzr2@csr.nih.gov.
Name of Committee: Infectious Diseases
and Immunology A Integrated Review Group;
Cellular and Molecular Immunology—A
Study Section.
Date: February 17–18, 2022.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Mohammad Samiul Alam,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 809D,
Bethesda, MD 20892, (301) 435–1199,
alammos@csr.nih.gov.
Name of Committee: Infectious Diseases
and Immunology A Integrated Review Group;
Bacterial Pathogenesis Study Section.
Date: February 17–18, 2022.
Time: 9:30 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Richard G Kostriken,
Ph.D., AB, BA Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Room 3192, MSC 7808, Bethesda, MD 20892,
(240) 519–7808, kostrikr@csr.nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Cardiovascular Differentiation and
Development Study Section.
Date: February 17, 2022.
Time: 9:30 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sara Ahlgren, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, RM 4136,
Bethesda, MD 20817–7814, (301) 435–0904,
sara.ahlgren@nih.gov.
Name of Committee: Cell Biology
Integrated Review Group; Cellular
Mechanisms in Aging and Development
Study Section.
Date: February 17–18, 2022.
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Time: 10:00 a.m. to 8:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tami Jo Kingsbury, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 710Q,
Bethesda, MD 20892, (410) 274–1352,
tami.kingsbury@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: January 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–00526 Filed 1–12–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2022–1 Phase I: Adjuvant Discovery for
Vaccines and for Autoimmune and Allergic
Diseases (Topic 104).
Date: February 7, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Tewary, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
E:\FR\FM\13JAN1.SGM
13JAN1
Federal Register / Vol. 87, No. 9 / Thursday, January 13, 2022 / Notices
20852, (301) 761–7219, tewaryp@
mail.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2022–1 Phase II: Adjuvant Discovery for
Vaccines and for Autoimmune and Allergic
Diseases (Topic 104).
Date: February 7, 2022.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Tewary, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761–7219, tewaryp@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: January 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–00527 Filed 1–12–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
jspears on DSK121TN23PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; PreClinical Medications Discovery and Abuse
Liability Testing for NIDA (8959).
Date: January 25, 2022.
Time: 12:00 p.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
VerDate Sep<11>2014
18:18 Jan 12, 2022
Jkt 256001
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Jenny Raye Browning,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Research, National Institute on Drug Abuse,
301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 443–4577,
jenny.browning@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; BRAIN
Initiative: Tools for Germline Gene Editing in
Marmosets (U01—Clinical Trial Not
Allowed).
Date: February 14, 2022.
Time: 2:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5819, gm145a@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
2169
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity Review.
Date: February 4, 2022.
Time: 3:00 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Video
Meeting).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
Division of Extramural Activities, NIDDK,
National Institutes of Health, Room 7353,
6707 Democracy Boulevard, Bethesda, MD
20892–2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: January 7, 2022.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2022–00477 Filed 1–12–22; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: January 10, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
National Institutes of Health
[FR Doc. 2022–00609 Filed 1–12–22; 8:45 am]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
PO 00000
Frm 00044
Fmt 4703
Sfmt 4703
National Institute of Mental Health;
Notice of Closed Meeting
Name of Committee: National Institute of
Mental Health Special Emphasis Panel;
Instrumentation Program (S10 Clinical Trial
Not Allowed).
Date: February 14, 2022.
Time: 11:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
E:\FR\FM\13JAN1.SGM
13JAN1
]]>Agencies
[Federal Register Volume 87, Number 9 (Thursday, January 13, 2022)]
[Notices]
[Pages 2168-2169]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-00527]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2022-1 Phase
I: Adjuvant Discovery for Vaccines and for Autoimmune and Allergic
Diseases (Topic 104).
Date: February 7, 2022.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Tewary, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD
[[Page 2169]]
20852, (301) 761-7219, [email protected].
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel; HHS-NIH-CDC-SBIR PHS 2022-1 Phase
II: Adjuvant Discovery for Vaccines and for Autoimmune and Allergic
Diseases (Topic 104).
Date: February 7, 2022.
Time: 2:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G56,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Poonam Tewary, Ph.D., Scientific Review Officer,
Scientific Review Program, Division of Extramural Activities,
National Institute of Allergy and Infectious Diseases, National
Institutes of Health, 5601 Fishers Lane, Room 3G56, Rockville, MD
20852, (301) 761-7219, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: January 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-00527 Filed 1-12-22; 8:45 am]
BILLING CODE 4140-01-P
